Literature DB >> 15754411

Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.

Xiao-Li Chen1, Bao-Shan Su, Run-Qin Sun, Jun Zhang, Yi-Li Wang.   

Abstract

AIM: To explore expression and distribution features of COX-2 and bcl-2 in human gastric adenocarcinoma tissues and to study its biological significance.
METHODS: Totally 36 human gastric carcinoma samples were enrolled in this study (cardiac adenocarcinoma 16 cases, distal gastric adenocarcinoma 20 cases). The expressions of COX-2 and bcl-2 in cancerous tissues and corresponding para-cancerous tissues were investigated by immunohistochemistry using COX-2 polyclonal antibody and bcl-2 monoclonal antibody. The normal gastric mucosa tissues were used as control.
RESULTS: The expressions of COX-2 and bcl-2 in gastric carcinoma were significantly higher than that in the para-cancerous tissues (77.8% vs 47.2%, P<0.01, 80.56% vs 58.33%, P<0.05). The expression of COX-2 in cardiac adenocarcinoma was remarkably higher than that in the distal gastric carcinoma (93.8% vs 65.0%, P<0.01). The expression of COX-2 was mainly localized in the cytoplasm of tumor cells and partly in the nucleus. There is a transition of the COX-2 cytoplasmic positivity to nucleic in tumor cells with the increase of gastric carcinoma pathological grade. Interstitial macrophages, fibroblasts and vascular endothelial cells also expressed COX-2. The tissues with higher expression of COX-2 also expressed high level of bcl-2 protein.
CONCLUSION: Abnormal expression pattern of COX-2 within the tissues of human gastric cancer is correlated with tumor location and lymph node metastasis. COX-2 may regulate expression of apoptosis suppressor gene (bcl-2) through interaction of tumor cells and stromal cells and play an important role in the generation and development of tumors, which will be of great help in developing new methods for antitumor therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754411      PMCID: PMC4250720          DOI: 10.3748/wjg.v11.i8.1228

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Cyclooxygenase-2 expression in hepatocellular carcinoma.

Authors:  G Shiota; M Okubo; T Noumi; N Noguchi; K Oyama; Y Takano; K Yashima; Y Kishimoto; H Kawasaki
Journal:  Hepatogastroenterology       Date:  1999 Jan-Feb

2.  Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.

Authors:  Jun Yu; Wai K Leung; Tin-Lap Lee; Pete C H Tse; Ka Fai To; Joseph J Y Sung
Journal:  Int J Oncol       Date:  2003-05       Impact factor: 5.650

3.  Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression.

Authors:  Y Higashi; T Kanekura; T Kanzaki
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

4.  Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.

Authors:  K Uefuji; T Ichikura; H Mochizuki
Journal:  J Surg Oncol       Date:  2001-01       Impact factor: 3.454

5.  Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.

Authors:  K S Chapple; E J Cartwright; G Hawcroft; A Tisbury; C Bonifer; N Scott; A C Windsor; P J Guillou; A F Markham; P L Coletta; M A Hull
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

6.  Host cyclooxygenase-2 modulates carcinoma growth.

Authors:  C S Williams; M Tsujii; J Reese; S K Dey; R N DuBois
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.

Authors:  O N Tucker; A J Dannenberg; E K Yang; F Zhang; L Teng; J M Daly; R A Soslow; J L Masferrer; B M Woerner; A T Koki; T J Fahey
Journal:  Cancer Res       Date:  1999-03-01       Impact factor: 12.701

8.  [Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia].

Authors:  T Zang; F Sun; Y Li
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2001-09

9.  Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis.

Authors:  Ai-Wen Wu; Jin Gu; Jia-Fu Ji; Zhen-Fu Li; Guang-Wei Xu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 10.  COX-2 inhibitors for the prevention of breast cancer.

Authors:  Louise R Howe; Andrew J Dannenberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

View more
  13 in total

Review 1.  Role of cyclooxygenase-2 in gastric cancer development and progression.

Authors:  Jian Cheng; Xiao-Ming Fan
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

2.  -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.

Authors:  Carina Pereira; Hugo Sousa; Paula Ferreira; Maria Fragoso; Luís Moreira-Dias; Carlos Lopes; Rui Medeiros; Mário Dinis-Ribeiro
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

3.  Overproduction of cyclo-oxygenase-2 (COX-2) is involved in the resistance to apoptosis in vascular smooth muscle cells from diabetic patients: a link between inflammation and apoptosis.

Authors:  S Redondo; E Ruiz; A Gordillo-Moscoso; J Navarro-Dorado; M Ramajo; E Rodríguez; F Reguillo; M Carnero; M Casado; T Tejerina
Journal:  Diabetologia       Date:  2010-10-19       Impact factor: 10.122

Review 4.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

5.  Expression of COX-2 in stomach carcinogenesis.

Authors:  Nora Manoukian Forones; Kharen Yaemi Kawamura; Helena Regina Comodo Segreto; Ricardo Artigiani Neto; Gustavo Rubino de Azevedo Focchi; Celina Tizuko Fujiyama Oshima
Journal:  J Gastrointest Cancer       Date:  2008-12-24

6.  Epstein-Barr virus-specific methylation of human genes in gastric cancer cells.

Authors:  Julie L Ryan; Richard J Jones; Shannon C Kenney; Ashley G Rivenbark; Weihua Tang; Elizabeth Rw Knight; William B Coleman; Margaret L Gulley
Journal:  Infect Agent Cancer       Date:  2010-12-31       Impact factor: 2.965

7.  Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature.

Authors:  Masoud Mireskandari; Ali Fakhr Shafaii; Gian Kayser; Klaus Kayser
Journal:  Diagn Pathol       Date:  2006-05-16       Impact factor: 2.644

8.  Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2.

Authors:  Ping Zhang; He-Sheng Luo; Ming Li; Shi-Yun Tan
Journal:  Onco Targets Ther       Date:  2015-04-16       Impact factor: 4.147

9.  Decreased expression of the β2 integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice.

Authors:  Aitor Benedicto; Joana Marquez; Alba Herrero; Elvira Olaso; Elzbieta Kolaczkowska; Beatriz Arteta
Journal:  BMC Cancer       Date:  2017-12-06       Impact factor: 4.430

10.  Association between COX-2 -1195G>A polymorphism and gastrointestinal cancer risk: A meta-analysis.

Authors:  Xiao-Wei Zhang; Jun Li; Yu-Xing Jiang; Yu-Xiang Chen
Journal:  World J Gastroenterol       Date:  2017-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.